Drug Database
IN

influenza vaccine

✓ Approved

Sinovac Biotech · Vaccine · Vaccine

What is influenza vaccine?

influenza vaccine is a vaccine developed by Sinovac Biotech. It is approved for therapeutic indications via injectable (others).

Drug Profile

CompanySinovac Biotech
Drug ClassVaccine, Large Molecules
RouteInjectable (Others)
StatusApproved
Sources: ClinicalTrials.gov, Sinovac Biotech

Related Research Articles

PubMedJournal of sleep research2026-11-11

2010 and 2013 Incidence Peaks in Narcolepsy and Idiopathic Hypersomnia Linked to Type A H1N1 and Type B Victoria Influenza Strains.

Zhang Zhongxing Z, Gool Jari K JK, Sirotkin Pavel P, Dauvilliers Yves Y et al.

Increased narcolepsy type-1 (NT1) incidence rates were reported globally in 2010, linked to the H1N1 2009-2010 influenza pandemic and Pandemrix vaccination. A child-specific NT1 peak was observed in Europe in 2013, further raising questions about the relationship between NT1 and influenza infections. This study analysed annual European incidence patterns of central disorders of hypersomnolence (CDH) in relation to influenza severity. All NT1 (N = 981) and a combined group of narcolepsy type-2 (NT2) and idiopathic hypersomnia (IH) (N = 545) cases from eight European centers were studied from 1995 to 2019. Linear mixed models and Spearman correlations were applied to investigate the relationships between CDH incidence and the severity of preceding influenza seasons, including H1N1, H3N2, and for the Netherlands, influenza Type B Victoria and Yamagata. Peaks in NT1 incidence were present in 2010 and 2013, while a 2010 child-specific peak was identified in NT2 and IH. Both groups showed a significantly positive correlation with H1N1 influenza severity and a negative correlation with H3N2. NT1 was also significantly associated with influenza Type B Victoria in the Netherlands, particularly in children. These findings suggest that, beyond H1N1, influenza Type B Victoria may be a novel trigger for NT1. Similar to NT1, the 2010 children peak in NT2 and IH may indicate possible immune-related pathophysiologies linked to the 2009-2010 H1N1 pandemic. Further immunological studies are warranted to unravel the complexities of these relationships and their implications for CDH.

PMID 43012367
Read full article →
PubMedClinical infectious diseases : an official publication of the Infectious Diseases Society of America2026-11-11

People With Influenza Requiring ICU Admission During the 2025-2026 Season, Marked by the Emergence of Influenza A(H3N2) Subclade K: A French Prospective Nationwide Cohort Study.

de Prost Nicolas N, Bay Pierre P, Le Goff Marie M, Préau Sébastien S et al.

Intense influenza activity has been reported alongside the emergence of influenza A(H3N2) subclade K. While epidemiological studies have reported heterogeneous findings regarding public health impact, data remain lacking on its impact on clinical phenotype of people requiring intensive care unit (ICU) admission. Prospective, multicenter, observational SEVARVIR cohort study including people admitted in 42 French ICUs with laboratory-confirmed influenza infection during the 2024-2025 and 2025-2026 seasons. Primary end point was day-28 mortality. Seven hundred twenty-six people were admitted for influenza in 2024-2025 (n = 360) and 2025-2026 (n = 366). In 2025-2026, influenza subtype was available for 265 people; 49% (n = 129) had A(H1N1)pdm09 and 51% (n = 136) had A(H3N2) subtype infection. Among the 40 people with A(H3N2) infection for whom whole-genome sequencing was available, 33 (82.5%) belonged to subclade K. In multivariable Cox analysis of the 2025-2026 season, age (adjusted hazard ratio, aHR = 1.04 [1.01;1.09]; P = .015), Clinical Frailty Scale (aHR = 1.59 [1.28;1.98]; P < .001), and sequential organ failure assessment score (aHR = 1.15 [1.05;1.26]; P = .003) were associated with an increased risk of death. In the 2024-2025/2025-2026 seasons or 2025-2026 season alone, influenza subtype was not associated with a significant risk of day-28 mortality. Phylogenetic analyses from our ICU cohort together with 600 contextual sequences from community-acquired influenza cases collected during the period showed no clustering according to severity. There was no evidence of an increased risk of death among critically ill people with influenza during the 2025-2026 season, despite the emergence of influenza A(H3N2) subclade K. NCT05162508.

PMID 43012657
Read full article →
PubMedClinical pharmacology and therapeutics2026-11-11

Antiviral Activity and Safety of Molnupiravir in Healthy Participants Inoculated With Influenza Virus: A Phase 2a, Randomized, Human Challenge Trial.

Nussbaum Jesse J, Mann Alex J AJ, Liao Laura E LE, Zhao Tian T et al.

Influenza viruses cause substantial global morbidity and mortality. Molnupiravir, an orally administered prodrug of β-D-N4-hydroxycytidine, has broad activity against RNA viruses, including influenza. A phase 2a, randomized, two-part human challenge trial in healthy adults (NCT05818124) was conducted to evaluate molnupiravir for influenza infection. In Part 1, 20 participants were inoculated with 106.26TCID50 of A/France/759/21 (H1N1) to establish infectivity, pathogenicity, and safety. After assessment of Part 1, a 10-fold lower virus dose was selected for Part 2 to delay time to peak viral load (PVL). In Part 2, 141 participants were randomized 1:1:1:1 to receive molnupiravir (5 days, 800 mg twice daily) postexposure prophylaxis (PEP; initiated 12 hours after inoculation), molnupiravir treatment (initiated 48 hours after inoculation), oseltamivir treatment (5 days, 75 mg twice daily, initiated 48 hours after inoculation), or placebo. Primary endpoints, assessed by quantitative viral culture, were PVL in all participants for PEP and viral load area under the curve (VL-AUC) in participants with confirmed infection for treatment. Lowering the viral inoculum delayed PVL by ~12 hours, although infection rates in the Part 2 placebo arm (40%) were lower than in Part 1 (75%). Molnupiravir PEP did not significantly reduce PVL compared with placebo but was associated with lower viral burden (difference in mean log10 VL-AUC -2.21 day*log10TCID50/mL; P = 0.03). No significant antiviral effect was observed with molnupiravir or oseltamivir treatment compared with placebo. Molnupiravir was well tolerated, with an adverse event profile similar to placebo. Although primary endpoints were not met, early administration of molnupiravir showed antiviral activity.

PMID 43010566
Read full article →
PubMedAsian cardiovascular & thoracic annals2026-11-11

Anatomical split-lobe resections versus lobectomy for left upper lobe NSCLC ≤3 cm: A propensity score-matched analysis.

Özer Erhan E, Şahin Fethiye Gizem FG, Melek Hüseyin H, Bayram Ahmet Sami AS et al.

BackgroundThe optimal extent of resection for left upper lobe nonsmall cell lung cancer (NSCLC) ≤ 3 cm remains controversial. Because the upper division and lingula represent two distinct bronchovascular units, anatomical split-lobe resection may provide an oncologically sound parenchyma-sparing alternative to left upper lobectomy (LUL). This study compared perioperative and long-term oncological outcomes between these procedures.MethodsThis single-center retrospective study included patients who underwent anatomical resection for pathological stage 0-II left upper lobe NSCLC ≤3 cm between 2010 and 2025. Among 199 eligible patients (145 LUL, 54 segmentectomy), 1:1 propensity score matching yielded 54 matched pairs. Perioperative outcomes, overall survival (OS), and recurrence-free survival (RFS) were analyzed.ResultsAfter matching, baseline characteristics were well balanced. Perioperative outcomes, including postoperative complications, prolonged air leak, length of hospital stay, and 30-day mortality, were comparable between groups. R0 resection was achieved in all patients. Five-year OS (67.1% vs. 63.4%, p = .585) and RFS (69.1% vs. 65.7%, p = .920) were similar between anatomical split-lobe resection and LUL. In multivariable analysis, increasing age and male sex were independently associated with worse OS, whereas resection type was not.ConclusionsAnatomical split-lobe resection (upper division segmentectomy or lingulectomy) provides perioperative and long-term oncological outcomes comparable to LUL in carefully selected patients with left upper lobe NSCLC measuring ≤3 cm.

PMID 43012542
Read full article →
PubMedMedComm2026-11-11

Therapeutic and Prophylactic Agents for Viral Diseases: Current Status, Challenges, and Future Prospects.

Khan Sawar S, Nisar Ayesha A, Li Xiaoxu X, Yu Hao H et al.

Viral diseases remain a major global health challenge despite substantial advances in vaccination, antiviral therapeutics, and public-health interventions. However, current antiviral strategies are still constrained by important gaps, including rapid viral evolution, limited broad-spectrum efficacy, immune escape, antiviral resistance, incomplete durability of protection, and inequitable global access to prevention and treatment. This review provides a comprehensive and integrated overview of contemporary antiviral prevention and therapeutic strategies, spanning vaccines, monoclonal antibodies, direct-acting antivirals, host-targeted therapies, immunomodulators, RNA-based therapeutics, gene-editing technologies, and cellular immunotherapies. We discuss the mechanistic foundations, clinical applications, pharmacologic considerations, and translational challenges associated with each modality across major human viral pathogens, including HIV, HBV, HCV, influenza, SARS-CoV-2, RSV, Ebola virus, arboviruses, and herpesviruses. Particular emphasis is placed on emerging innovations such as long-acting prophylaxis, Fc-engineered monoclonal antibodies, nanoparticle and mucosal vaccine platforms, CRISPR-based antiviral systems, and broadly protective host-directed approaches designed to overcome resistance and enhance pandemic preparedness. In addition, we highlight the growing importance of real-time genomic surveillance and equitable global deployment strategies in shaping future antiviral responses, collectively underscoring that the next generation of antiviral medicine will depend on the convergence of universal immunization strategies, durable therapeutics, precision immune modulation, and rapidly deployable platform technologies capable of addressing both endemic and emerging viral threats.

PMID 43011527
Read full article →
PubMedAnalytical chemistry2026-11-11

Turning DNAzyme into a Stitch-to-Activate Biosensor for Single-Base-Resolution Molecular Diagnostics.

Wang Xiangran X, Lu Xinxin X, Yang Zhengquan Z, Du Jiangchuan J et al.

The catalytic core of DNAzymes is highly sensitive to local structural perturbations. Conventional DNAzyme-based SNV sensing mainly relies on differences in hybridization stability between matched and mismatched targets. Here, we position the SNV immediately adjacent to the catalytic-core reconstitution junction of a split DNAzyme, allowing a single-base mismatch to directly affect the catalytic core reconstitution and subsequent substrate cleavage. Systematic analysis of insertions, deletions, and substitutions within the catalytic core further confirmed the strong dependence of DNAzyme activity on local core structure. To enhance serum stability and sustained catalytic performance, we anchored the split probes onto cholesterol-modified micelles (DZM). Micellar confinement protects against nuclease degradation and promotes efficient repeated catalytic turnover, resulting in enhanced signal accumulation. DZM achieves a 100 fM detection limit and a two-fold higher signal-to-noise ratio than the free split DNAzyme, and discriminates KRAS G12D at a mutant fraction as low as 0.1%. Clinical validation on serum samples yields an AUC of 0.9940. The stitch-to-activate design also enables multiplexed detection by incorporating distinct recognition arms at the same junction, allowing simultaneous interrogation of multiple variants in one pot. This modular architecture is reprogrammable and compatible with DNA logic gates, offering a cost-effective liquid biopsy tool.

PMID 43010411
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about influenza vaccine